AI Article Synopsis
- Hemophagocytic lymphohistiocytosis (HLH) is a severe inflammatory syndrome that can arise from SARS-CoV-2 infection, complicating diagnosis and treatment.
- An older male patient developed HLH after a mild COVID-19 infection; initially, he only had a fever, but his condition worsened during his hospital stay.
- Despite poor response to standard therapies, he was successfully treated with ruxolitinib, highlighting its potential as a treatment for HLH associated with COVID-19.
Article Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. SARS-CoV-2 infection can induce secondary HLH, as described in previous case reports, but diagnosis and treatment are challenging.
Case Study: We described an older male patient diagnosed with HLH related to previous SARS-CoV-2 infection. Fever was the only clinical manifestation initially but deterioration in clinical condition and laboratory parameters was observed during hospitalization. He responded poorly to classical therapy but was successfully treated with ruxolitinib.
Conclusion: Clinicians should be aware of the possibility of HLH secondary to mild SARS-CoV-2 infection and take timely therapeutic measures to inhibit an inflammatory factor storm. Ruxolitinib is a potential choice for COVID-19 related HLH.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149062 | PMC |
| http://dx.doi.org/10.2147/IDR.S384035 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!